DRG Fingertip Insights Reports
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Formulary Advantages in Therapies for Multiple Sclerosis: Health plans await the arrival of orally administered therapies to compete with existing brands
With increased diagnosis rates and higher drug prices for multiple sclerosis (MS), U.S. health plans have grown more focused on their coverage of and spending on MS therapies. Partly because of the pr…
Formulary Advantages in Oral Oncology Drugs: Health plans respond to generic entry, base formulary decisions on survival data
Private and Medicare plans will continue their receptiveness to oral oncology therapies over the next five years, but anticipated increases in coinsurance rates and copays will shift more of the cost…